Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
Status:
Completed
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the safety and tolerability of sunitinib
alternating with regorafenib in participants with advanced gastrointestinal stromal tumor
GIST, if the standard approved therapies (imatinib, sunitinib and regorafenib) have failed to
control the disease. Additionally, this study seeks to determine the highest dose that can be
given safely for this combination of drugs.